肝炎早筛：拥抱肝炎防治刚需，领航市场新机遇 头豹词条报告系列

Investment Rating - The report does not explicitly state an investment rating for the hepatitis early screening industry Core Insights - The hepatitis early screening industry is characterized by high technical barriers, significant market potential, and a clear business model. The global and Chinese markets show immense demand for hepatitis early screening, driven by the high number of hepatitis patients and low awareness and diagnosis rates in China. The market size grew from 31.165 billion RMB in 2018 to 54.919 billion RMB in 2023, with a compound annual growth rate (CAGR) of 12.00% [5][35]. It is projected to reach 78.142 billion RMB by 2028, with a CAGR of 6.98% from 2024 to 2028 [5][35]. Summary by Sections Industry Definition - Hepatitis is an inflammation of the liver caused by various factors, including viral infections. The early screening industry aims to identify potential hepatitis patients before symptoms appear, facilitating early diagnosis and treatment [6]. Industry Characteristics - The industry features high technical barriers, a broad market outlook, and a well-defined business model. The demand for hepatitis early screening is substantial due to the disease's association with liver cancer and the increasing public health awareness [12][14][15]. Development History - The industry has evolved through three main phases: the nascent phase (1990s to 2016), the initiation phase (2016 to 2018), and the rapid development phase (2018 to present). Each phase has seen advancements in technology and increased public and governmental focus on hepatitis screening [16][19]. Industry Chain Analysis - The industry chain consists of upstream suppliers of reagents and equipment, midstream medical testing institutions, and downstream consumers, including the general and high-risk populations. The integration of these segments is crucial for enhancing efficiency and service quality [20][30][33]. Market Size and Growth - The market size for hepatitis early screening has shown significant growth, with a historical increase from 31.165 billion RMB in 2018 to 54.919 billion RMB in 2023. The future growth is supported by government initiatives and increasing public health awareness [35][39]. Competitive Landscape - The competitive landscape features a tiered structure, with leading companies like BGI and KingMed Diagnostics at the forefront. These companies leverage technological advancements and extensive testing networks to enhance their market positions [46][49]. Policy Environment - Government policies play a crucial role in promoting hepatitis screening, with initiatives aimed at increasing screening rates and improving public health outcomes. The "14th Five-Year Plan" emphasizes enhancing public health services and disease prevention [43][45]. Future Outlook - The hepatitis early screening industry is expected to continue its growth trajectory, driven by technological innovations, increased public awareness, and supportive government policies. The focus on integrating testing services and improving screening accuracy will be key to meeting future demands [21][39][50].